Skip to content
OpenCapital
Get started

KORU Medical Systems KRMD Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

InfuSystem Holdings logo
InfuSystem HoldingsINFU
——
ICU Medical logo
ICU MedicalICUI
——

Other financials

Income statement

See full
Revenue$11.8M+22.1%
Gross profit$7.2M+19.6%
Operating income-$864.9K+30.5%
Net income-$807.1K+30.8%
EPS (diluted)-$0.02+33.3%

Balance sheet

See full
Cash & equivalents$8.8M+0.4%
Total debt$3.5M-2.8%
Total equity$16.9M+3.5%
Total assets$28.6M+5.1%

Cash flow

See full
Operating cash flow$14.7K+106%
CapEx$46.2K-89.6%
Free cash flow-$31.5K+95.4%

Valuation

See full
Market cap$206.24M+24.9%
Enterprise value$200.96M+25.1%
P/S4.8×+0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin-6%-2.3pp
Net margin-5.3%-2.1pp
FCF margin-37.1%+23.7pp

Returns & leverage

See full
Return on equity-13.7%-4.8pp
Debt / equity0.2×0.0×
Current ratio2.3×-0.1×

Where this comes from

Reported directly by KORU Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: KORU Medical Systems’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KORU Medical Systems's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KORU Medical Systems's indefinite-lived research and development assets?
KORU Medical Systems (KRMD) reported indefinite-lived research and development assets of $1.28M in Q4 2025.
What is the long-term trend for KORU Medical Systems's indefinite-lived research and development assets?
Over 2 years (2023 to 2025), KORU Medical Systems's indefinite-lived research and development assets has grown at a -21.0% compound annual growth rate (CAGR), from $2.05M to $1.28M.
What does indefinite-lived research and development assets mean?
These are acquired in-process research and development assets that have not yet reached commercial viability and are therefore not subject to amortization. They represent the capitalized value of the company's innovation pipeline and future growth potential. Changes in this balance indicate the progress or impairment of long-term strategic R&D investments.